Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

URGN Urogen Pharma Ltd.

Market Closed 12-19 16:00:00 EST

22.80

+1.08

+4.97%

盘后22.80

+0.000.00%

16:56 EST

High23.20	Low21.72	Vol540.80K
Open21.90	D1 Closing21.72	Amplitude6.81%
Mkt Cap1.07B	Tradable Cap844.37M	Total Shares46.81M
T/O12.32M	T/O Rate1.46%	Tradable Shares37.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"URGN","market":"US","secType":"STK","nameCN":"Urogen Pharma Ltd.","latestPrice":22.8,"timestamp":1766178000000,"preClose":21.72,"halted":0,"volume":540795,"hourTrading":{"tag":"盘后","latestPrice":22.8,"preClose":22.8,"latestTime":"16:56 EST","volume":73177,"amount":1671693.2515,"timestamp":1766181383056},"delay":0,"floatShares":37033665,"shares":46808892,"eps":-3.460625,"marketStatus":"Market Closed","change":1.08,"latestTime":"12-19 16:00:00 EST","open":21.9,"high":23.2,"low":21.72,"amount":12318470.78616,"amplitude":0.06814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.460625,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NASDAQ","adjPreClose":21.72,"preHourTrading":{"tag":"盘前","latestPrice":21.87,"preClose":21.72,"latestTime":"09:29 EST","volume":753,"amount":16443.309945,"timestamp":1766154599525},"postHourTrading":{"tag":"盘后","latestPrice":22.8,"preClose":22.8,"latestTime":"16:56 EST","volume":73177,"amount":1671693.2515,"timestamp":1766181383056},"volumeRatio":0.4383716496089374,"impliedVol":0.6522,"impliedVolPercentile":0.288},"requestUrl":"/m/hq/s/URGN/wiki","defaultTab":"wiki","newsList":[{"id":"2589897625","title":"UroGen Pharma Grants Inducement RSUs to 14 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897625?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:00","pubTimestamp":1764939610,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. has granted inducement restricted stock units  to 14 new employees, with up to 32,500 ordinary shares issuable upon vesting and settlement. The RSUs will vest equally over three years, with one-third of the shares vesting each year on the anniversary of the grant date, contingent on continued employment with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL660cFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","LU2210150020.SGD","NDAQ","URGN","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2585503154","title":"UroGen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585503154","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585503154?lang=en_us&edition=fundamental","pubTime":"2025-11-21 02:43","pubTimestamp":1763664184,"startTime":"0","endTime":"0","summary":"Mark Schoenberg, Chief Medical Officer of Urogen Pharma Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL4W5DDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UroGen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2583666188","title":"UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666188","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583666188?lang=en_us&edition=fundamental","pubTime":"2025-11-16 15:16","pubTimestamp":1763277416,"startTime":"0","endTime":"0","summary":"In early November 2025, UroGen Pharma reported third-quarter results, highlighted by preliminary Phase 3 data showing a 77.8% complete response for UGN-103 in treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and received FDA feedback supporting a potential New Drug Application for this therapy.\nThis regulatory milestone not only validates UroGen’s clinical development approach but also indicates a clearer path toward new product approvals in the urothelial...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/ugn-103-phase-3-success-and-fda-support-could-be-a-game-chan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/ugn-103-phase-3-success-and-fda-support-could-be-a-game-chan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2581887714","title":"Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887714?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:37","pubTimestamp":1762533431,"startTime":"0","endTime":"0","summary":"In a report released today, Aydin Huseynov from Ladenburg Thalmann & Co. reiterated a Buy rating on Urogen Pharma, with a price target of $55.00. A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ladenburg-thalmann-co-sticks-to-its-buy-rating-for-urogen-pharma-urgn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ladenburg-thalmann-co-sticks-to-its-buy-rating-for-urogen-pharma-urgn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["URGN"],"gpt_icon":0},{"id":"1189324090","title":"Stock Track | UroGen Pharma Plummets 5.06% in Pre-market: Potential Profit-Taking After Recent Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1189324090","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189324090?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:33","pubTimestamp":1762526039,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. (URGN) shares plummeted 5.06% in pre-market trading on Friday, marking a significant reversal from its recent upward trajectory. This downturn comes on the heels of an impressive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"1120149579","title":"Stock Track | Urogen Pharma Plummets 5.06% in Pre-market Despite Recent Positive Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=1120149579","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120149579?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:33","pubTimestamp":1762526027,"startTime":"0","endTime":"0","summary":"Urogen Pharma Ltd. (URGN) shares plunged 5.06% in pre-market trading on Friday, surprising investors given the company's recent string of positive developments. This decline comes on the heels of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"1188461729","title":"Stock Track | UroGen Pharma Plunges 8.16% as Q3 Revenue Misses Estimates Despite Promising Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1188461729","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188461729?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:46","pubTimestamp":1762479980,"startTime":"0","endTime":"0","summary":"Shares of UroGen Pharma Ltd. (URGN) tumbled 8.16% in Thursday's trading session following the release of its third-quarter 2025 financial results. The biotechnology company, focused on urologic and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"1172366662","title":"Stock Track | Urogen Pharma Plunges 8% Following Q3 Earnings Miss and Mixed Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1172366662","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172366662?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:46","pubTimestamp":1762479975,"startTime":"0","endTime":"0","summary":"Shares of Urogen Pharma Ltd. (URGN) plummeted 8.16% in Thursday's trading session following the release of the company's third-quarter 2025 financial results and subsequent earnings call. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"1122470500","title":"UroGen Q3 2025 Earnings Call Summary and Q&A Highlights: Zasturi Launch and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1122470500","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122470500?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:06","pubTimestamp":1762445166,"startTime":"0","endTime":"0","summary":"[Management View]UroGen Pharma Ltd. reported cash reserves of over $127 million, which management believes will support operations through profitability if current plans are maintained. The launch of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"gpt_icon":0},{"id":"2581976090","title":"UroGen (URGN) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2581976090","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581976090?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:03","pubTimestamp":1762444989,"startTime":"0","endTime":"0","summary":"DATEThursday, Nov. 6, 2025 at 10 a.m. ETCALL PARTICIPANTSChief Executive Officer — Kelsey GoodwinChief Financial Officer — Christopher DegnanChief Commercial Officer — David LinChief Medical Officer — Mark P. SchoenbergNeed a quote from a Motley Fool analyst?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/06/urogen-urgn-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/06/urogen-urgn-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["URGN"],"gpt_icon":0},{"id":"2581970500","title":"UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2581970500","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581970500?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:36","pubTimestamp":1762443389,"startTime":"0","endTime":"0","summary":"UroGen Pharma (URGN) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"1103575041","title":"Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1103575041","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103575041?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:12","pubTimestamp":1762434759,"startTime":"0","endTime":"0","summary":"Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"1164654050","title":"Stock Track | Urogen Pharma Plunges 9.37% Pre-market Following Q3 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1164654050","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164654050?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:12","pubTimestamp":1762434736,"startTime":"0","endTime":"0","summary":"Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results. The biotech company's performance...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["URGN"],"gpt_icon":0},{"id":"2581093457","title":"Earnings Flash (URGN) UroGen Pharma Posts Q3 Net Loss $0.69 a Share, vs. FactSet Est of $0.69 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093457","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093457?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434205,"startTime":"0","endTime":"0","summary":"Earnings Flash (URGN) UroGen Pharma Posts Q3 Net Loss $0.69 a Share, vs. FactSet Est of $0.69 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["URGN"],"gpt_icon":0},{"id":"2581093325","title":"UroGen Pharma reports Q3 revenue of $27.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093325?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:01","pubTimestamp":1762434104,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. reported third quarter 2025 financial results with total revenue of $27.5 million, up from $25.2 million in the same period last year. For the nine months ended September 30, 2025, revenue reached $72.0 million, compared to $65.8 million for the same period in 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $127.4 million, down from $241.7 million at December 31, 2024. Total assets stood at $185.0 million, with total liabilities at $300.5 million and a total shareholders' deficit of $115.4 million. ZUSDURI achieved net product revenue of $1.8 million in the third quarter, with preliminary October demand revenue estimated at $4.5 million. JELMYTO recorded net product revenue of $25.7 million in the third quarter, reflecting a 13% year-over-year growth in underlying demand revenue. UroGen expects full-year 2025 operating expenses to range from $215 to $225 million, including $11 to $14 million in non-cash share-based compensati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLc4B7g6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","URGN","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","NDAQ","BK4588"],"gpt_icon":0},{"id":"2581109334","title":"UroGen Pharma Reports 77.8% Complete Response Rate in Phase 3 UTOPIA Trial for UGN-103","url":"https://stock-news.laohu8.com/highlight/detail?id=2581109334","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581109334?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:58","pubTimestamp":1762433913,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. has announced preliminary results from its ongoing Phase 3 UTOPIA trial, evaluating UGN-103  for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer . The trial demonstrated a 77.8% three-month complete response rate . The company also reported that the U.S. Food and Drug Administration  has agreed that the complete response and durability results from the UTOPIA trial may support the submission of a New Drug Application  for UGN-103 for this indication. UGN-103 is designed to provide manufacturing and reconstitution improvements over the currently approved ZUSDURI  while maintaining prolonged drug exposure within the bladder. The NDA submission is planned for 2026. The results were announced publicly and are based on preliminary data from the ongoing study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL86CrnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","URGN","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2580755628","title":"Urogen Pharma Ltd  expected to post a loss of 69 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580755628","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580755628?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:09","pubTimestamp":1762268959,"startTime":"0","endTime":"0","summary":"Urogen Pharma Ltd  expected to post a loss of69cents a share - Earnings Preview Urogen Pharma Ltd URGN.OQ, URGN.O is expected to  show a rise in quarterly revenue when it reports  results on November ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG28J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"gpt_icon":0},{"id":"2579146337","title":"UroGen Pharma Ltd. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579146337","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579146337?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825640,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. will report third quarter 2025 financial results on Thursday, November 6th, 2025. The results will be released prior to the open of the stock market on UroGen's Investor Relations website. A live audio webcast and conference call to present the results is scheduled for November 6th, 2025, at 10:00 AM ET and can be accessed on the UroGen's Investor Relations website. A replay will be available on the site for approximately 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on October 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5ss6Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","URGN","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2578837642","title":"Analysts’ Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578837642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578837642?lang=en_us&edition=fundamental","pubTime":"2025-10-27 21:30","pubTimestamp":1761571813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN – Research Report), AngioDynamic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-urogen-pharma-urgn-angiodynamics-ango-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-urogen-pharma-urgn-angiodynamics-ango-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","BK4585","BK4588","URGN","LU0029874061.USD","LU0128526141.USD","XLV","ANGO","HCSG","LABU","XBI","BK4581","BK4082"],"gpt_icon":0},{"id":"2578134649","title":"UroGen Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2578134649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578134649?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:49","pubTimestamp":1761569340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 08:49 ET (12:49 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.urogen.com","stockEarnings":[{"period":"1week","weight":0.0459},{"period":"1month","weight":-0.0977},{"period":"3month","weight":0.2702},{"period":"6month","weight":0.5563},{"period":"1year","weight":1.1289},{"period":"ytd","weight":1.1408}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.05646},{"month":2,"riseRate":0.25,"avgChangeRate":-0.051697},{"month":3,"riseRate":0.375,"avgChangeRate":-0.010399},{"month":4,"riseRate":0.5,"avgChangeRate":0.047834},{"month":5,"riseRate":0.25,"avgChangeRate":-0.135298},{"month":6,"riseRate":0.777778,"avgChangeRate":0.327988},{"month":7,"riseRate":0.444444,"avgChangeRate":0.12723},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030454},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.046538},{"month":10,"riseRate":0.555556,"avgChangeRate":0.023022},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096296},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.076478}],"exchange":"NASDAQ","name":"Urogen Pharma Ltd.","nameEN":"Urogen Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Urogen Pharma Ltd.,URGN,Urogen Pharma Ltd.股票,Urogen Pharma Ltd.股票老虎,Urogen Pharma Ltd.股票老虎国际,Urogen Pharma Ltd.行情,Urogen Pharma Ltd.股票行情,Urogen Pharma Ltd.股价,Urogen Pharma Ltd.股市,Urogen Pharma Ltd.股票价格,Urogen Pharma Ltd.股票交易,Urogen Pharma Ltd.股票购买,Urogen Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction